<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Snowden, J A</style></author><author><style face="normal" font="default" size="100%">Saccardi, R</style></author><author><style face="normal" font="default" size="100%">Allez, M</style></author><author><style face="normal" font="default" size="100%">Ardizzone, S</style></author><author><style face="normal" font="default" size="100%">Arnold, R</style></author><author><style face="normal" font="default" size="100%">Cervera, R</style></author><author><style face="normal" font="default" size="100%">Denton, C</style></author><author><style face="normal" font="default" size="100%">Hawkey, C</style></author><author><style face="normal" font="default" size="100%">Labopin, M</style></author><author><style face="normal" font="default" size="100%">Mancardi, G</style></author><author><style face="normal" font="default" size="100%">Martin, R</style></author><author><style face="normal" font="default" size="100%">Moore, J J</style></author><author><style face="normal" font="default" size="100%">Passweg, J</style></author><author><style face="normal" font="default" size="100%">Peters, C</style></author><author><style face="normal" font="default" size="100%">Rabusin, M</style></author><author><style face="normal" font="default" size="100%">Rovira, M</style></author><author><style face="normal" font="default" size="100%">van Laar, J M</style></author><author><style face="normal" font="default" size="100%">Farge, D</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">EBMT Autoimmune Disease Working Party (ADWP)</style></author><author><style face="normal" font="default" size="100%">Paediatric Diseases Working Party (PDWP)</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.</style></title><secondary-title><style face="normal" font="default" size="100%">Bone Marrow Transplant</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bone Marrow Transplant.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Autoimmune Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical Trials, Phase I as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Clinical Trials, Phase II as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">European Union</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Safety</style></keyword><keyword><style  face="normal" font="default" size="100%">Severity of Illness Index</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012 Jun</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">47</style></volume><pages><style face="normal" font="default" size="100%">770-90</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/22002489?dopt=Abstract</style></custom1></record></records></xml>